Quest Diagnostics posts Q3 2026 results, raises full‑year revenue and EPS outlook
Quest Diagnostics reported third‑quarter 2026 revenue of about $3.10 billion, a 10% year‑over‑year increase, and adjusted earnings per share of $3.00, up 15.4% from the prior year. The company lifted its full‑year 2026 revenue guidance to a range of $12.065 billion‑$12.105 billion and its adjusted EPS guidance to $11.25‑$11.35. Management highlighted strong volume growth, new Apple Health app lab ordering, and an upcoming acquisition of outreach lab assets, while noting a potential 1% revenue headwind from PAMA reimbursement changes in 2027.
Why it matters
The raised guidance signals higher expected earnings and cash flow for the year, which may support a higher valuation for DGX. Management also warned that PAMA reimbursement cuts could reduce 2027 revenue by roughly 1%, a risk investors should consider.
Key facts
- 1Q3 2026 revenue was $3.10 billion, up 10% YoY. stocktitan.net
- 2Adjusted diluted EPS for Q3 was $3.00, up 15.4% YoY. stocktitan.net
- 3Full‑year 2026 revenue guidance was raised to $12.065 billion‑$12.105 billion. stocktitan.net
- 4Full‑year 2026 adjusted EPS guidance was raised to $11.25‑$11.35 per share. stocktitan.net
- 5Operating income for the quarter was $479 million, up from $386 million YoY. sec.gov
- 6Management expects the PAMA reimbursement change to cut 2027 revenue by about 1%. finance.yahoo.com
Summary written by AlphAI AI Desk from 18 of 18 sources. Not investment advice. Figures are as stated by the linked sources.